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Abstract 
Glioblastoma (GBM) is an aggressive and incurable primary brain tumour that causes severe neurological, 
cognitive, and psychological symptoms. Symptoms are caused and exacerbated by the infiltrative 
properties of GBM cells, which enable them to pervade the healthy brain and disrupt normal function. 
Recent research has indicated that, while radiotherapy (RT) remains the most effective component of 
multimodality therapy for GBM patients, it can provoke a more infiltrative phenotype in GBM cells that 
survive treatment. Here we demonstrate an essential role of the actin-myosin regulatory kinase myotonic 
dystrophy kinase-related CDC42- binding kinase (MRCK) in mediating the pro-invasive effects of radiation. 
MRCK-mediated invasion occurred via downstream signalling to effector molecules MYPT1 and MLC2. 
MRCK was activated by clinically relevant doses per fraction of radiation, and this activation was 
concomitant with an increase in GBM cell motility and invasion. Furthermore, ablation of MRCK activity 
either by RNAi or by inhibition with the novel small molecule inhibitor BDP-9066 prevented radiation-
driven increases in motility both in vitro and in a clinically relevant orthotopic xenograft model of GBM. 
Crucially, treatment with BDP-9066 in combination with RT significantly increased survival in this model and 
markedly reduced infiltration of the contralateral cerebral hemisphere. 
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Introduction 
Glioblastoma (GBM) is the most common and most aggressive primary brain tumour and is currently 
incurable. Poor outcomes are caused in part by the highly infiltrative nature of GBM tumour cells. This 
property enables them to disseminate through the brain via existing white matter tracts and perivascular 
spaces, making complete surgical resection unachievable and contributing to high recurrence rates. 
Therefore, despite aggressive treatment with surgery, radiotherapy and chemotherapy, overall survival 
remains extremely poor, with patients experiencing an average life expectancy of approximately one year 
[1]. Targeting the molecular mechanisms that underlie the invasive nature of GBM has the potential to 
increase survival and alleviate some of the devastating neurological disabilities associated with infiltrative 
disease.  
The vast majority of patients with GBM receive radiotherapy as the central component of their first-line 
tƌeatŵeŶt. Studies iŶ the late ϭϵϳϬ͛s shoǁed that ƌadiĐal ƌadiotheƌapǇ douďles suƌǀiǀal fƌoŵ approximately 
6 to 12 months [2]; in 2005 a further improvement from 12 to 14 months was achieved by adding 
concomitant and adjuvant temozolomide to radiotherapy [1]. Every other phase III trial in this disease has 
been negative. It is universally accepted, therefore, that any novel therapies tested in the first-line setting 
must be added to a radiotherapy-based treatment schedule.  
Despite its proven benefits, it is clear that radiation can also adversely affect tumour cell behaviour through 
alterations in cell signalling and gene expression profiles. As early as 2001, there have been studies 
indicating that sub-lethal doses of radiation can promote GBM cell motility and infiltration in vitro and in 
vivo [3, 4].  These early reports have recently been given renewed attention following the publication of a 
number of new studies [5-7]. The concept that radiotherapy can promote a more aggressive, infiltrative 
phenotype in those GBM cells that survive treatment is consistent with the repeated finding that escalating 
radiotherapy dose does not improve outcomes for GBM patients [8]. It also has profound implications for 
the development of new therapeutic avenues and highlights the need for a greater understanding of the 
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mechanisms that drive these changes so that new therapeutic targets can be identified and explored. For 
example, the failure of high radiation doses to achieve tumour control may be partly explained by tumour 
cells migrating outside of the irradiated volume during the treatment period. 
Migration and invasion of tumour cells are driven by mechanical forces generated by changes in 
contractility of the actin-myosin cytoskeleton [9]. The Rho family of small GTPases comprises key regulators 
of actin-myosin contractility and has been widely implicated in metastasis and invasion [10, 11].  Indeed the 
role of RhoGTPases in GBM has been interrogated by a number of researchers, and whilst their results 
support a pivotal role for small GTPases and their downstream effectors, teasing out their specific 
contributions has proved complex, with different studies returning contradictory results [12].  
RhoGTPases act via downstream effector kinases such as Rho-associated protein kinase (ROCK) and 
myotonic dystrophy kinase-related CDC42-binding kinase (MRCK). These downstream kinases regulate 
contractility of the cytoskeleton by activating phosphorylation of myosin light chain proteins (MLC) and 
inactivating the myosin phosphatase subunit MYPT1 to facilitate the cytoskeletal changes that are 
responsible for different modes of cell motility. The ͚aŵoeďoid͛ mode of invasion is characterised by 
rounded cell morphology and is highly dependent on ROCK activity [13].  Considerable effort has been 
invested in the development of ROCK inhibitors that could oppose RhoA driven cancer cell motility and 
metastasis. However, although ROCK inhibitors do indeed display strong efficacy in opposing cancer cell 
invasion and metastasis in vitro and in vivo [14], their clinical development has not progressed because of 
adverse effects on the cardiovascular system.  
In contrast, mesenchymal invasion, which is classically adopted by infiltrating glioma cells, requires activity 
of the M‘CK isofoƌŵs α aŶd β that lie downstream of the RhoGTPase protein CDC42. This mode of invasion 
is characterised by an elongated cell body, actin-rich protrusions and actin-myosin contractility at the rear 
of the migrating cells. Unbekandt et al have recently demonstrated that MRCK can drive cancer cell 
migration, a process which can be inhibited by specific small molecule inhibitors [15-17]. Since CDC42 
activity is upregulated in glioma [18, 19] and may drive the mesenchymal mode of migration employed by 
infiltrating glioma cells, we investigated a potential role for MRCK driven GBM cell invasion in the 
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pathogenesis of glioblastoma. In this study we demonstrate that MRCK activity is upregulated at the 
invasive edges of GBM tumours and is further enhanced by irradiation both in vitro and in vivo. We show 
that this response is essential to the phenomenon of radiation induced migration of GBM cells in a relevant 
in vivo model of GBM. Furthermore, by demonstrating complete abrogation of radiation driven invasion in 
this model using a novel small molecule inhibitor of MRCK, we confirm the pivotal role of MRCK in driving 
radiation induced infiltration and validate it as a novel and highly promising anti-invasive therapeutic target 
in GBM.  
Materials and Methods 
Cell culture and Radiation treatments 
E2 and G7 cell lines were obtained from Colin Watts (Cambridge) and are derived from anonymized patient 
resection specimens as previously described [20, 21]. Cell lines were routinely cultured on Matrigel coated 
plates (0.23 mg/l in AdDMEM, Life Technologies) in serum free AdDMEM supplemented with 20ng/ml EGF, 
10ng/ml FGF, 0.5% B27 supplement and 0.5% N2 supplement (all Life Technologies) with the exception of 
E2 cells for ex vivo migration assays which were cultured in MEM (Life Technologies) with 10% FBS. The 
commercially available U87MGluc2 line (Caliper Life Sciences) was cultured in MEM EBSS (Life 
Technologies), 10% FBS, 1% L-glutamine, 1 % NEAA (Life Technologies) and 1% NaPyruvate (Life 
Technologies). 
Cells were irradiated using an Xstrahl RX225 radiation cabinet (195 kV X-rays, dose rate 1.39 Gy/minute). 
Cell line testing 
All cell lines were used in experiments between passage 2 and passage 12 from thawing and tested for 
mycoplasma every three months, most recent date Aug 2018. U87MGluc2 line is an authenticated cell line 
received from Caliper Life Sciences. E2 and G7 cell lines are primary patient-derived cell lines and as such 
no separate cell authentication was under taken. 
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Subconfluent and ex vivo migration assays 
For subconfluent migration assays, 2 x 10
5 
cells per well were plated at in 6 well dishes and migration 
imaged by timelapse microscopy capturing images every 15 mins. Migration velocity was calculated using 
single cell tracking via ImageJ analysis. 
For ex vivo migration assays, cell were seeded onto fresh 1 mm coronal brain slices obtained from 6-8 week 
old C57BL/6 mice in culture medium (described above) and allowed to establish overnight with incubation 
at 37
o
C, 5% CO2. BƌaiŶ sliĐes ǁeƌe theŶ iŶǀeƌted oŶto Luŵoǆ ϯϱ ŵŵ dishes ;ϴ μŵ, SaƌstedtͿ aŶd seĐuƌed 
with Nuclepore Track-Etch membrane (Whatman) sealed with Matrigel. Migration was captured via 
confocal timelapse microscopy with images taken every 15 mins. Migration velocity was calculated using 
single cell tracking via ImageJ analysis. 
Clonogenic assays 
Cells were plated onto 6 well plates in triplicate per biological repeat. 24 hours after plating, cells were 
treated with DMSO or 250 µM BDP-9066 for 2 hours followed by radiation treatment and media 
replacement. Cells were fixed after 2-3 weeks, stained with crystal violet and colonies counted manually. 
Data was fitted using a linear quadratic model. 
siRNA transfection and Western blotting 
Gϳ Đells ǁeƌe tƌaŶsfeĐted ǁith ϭϬ ŶM si‘NA taƌgetiŶg M‘CKα aŶd/oƌ β oƌ ĐoŶtƌol sĐƌaŵďled si‘NA 
;DhaƌŵaĐoŶ; M‘CKα AAGAAUAUCUGCUGUGUUU, M‘CKβ GAAGAAUACUGAACGAAUU, M‘CKα+β 
CGAGAAGACUUUGAAAUAAUU) using RNAiMAX reagent (Life Technologies) and incubated for 48 hours 
prior to imaging or protein extraction. 
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For Western blotting, protein was extracted using 1% SDS/50 mM Tris pH 6.8 supplemented with protease 
and phosphatase inhibitors (Roche) and subject to SDS-PAGE and protein transfer. Membranes were 
probed using antibodies listed in supplemental table 1. 
Immunofluorescence 
3 x 10
3
 irradiated or untreated E2 cells were plated in each well of a 96 well glass bottomed plate pre-
coated with Matrigel and allowed to adhere for 2-3 hours before replacement of media with media 
containing DMSO or the indicated amount of BDP-9066 and incubated overnight. Cells were washed with 
PBS and fixed with 4% paraformaldehyde followed by permeabilisation with 0.1% TritonX/TBS. Cells were 
washed with TBS-Tween and blocked with 1% BSA/TBST followed by incubation with 1:200 pMLC2 antibody 
;AďĐaŵ Đat#ϯϲϳϱͿ foƌ ϭ houƌ at ƌooŵ teŵpeƌatuƌe. Cells ǁeƌe ǁashed aŶd iŶĐuďated ǁith ǁith ϮϬ μl/ŵl 
Alexa 488 anti-mouse secondary antibody, 1:40 TR phalloidin stain, 1:300 DAPI and 1:10000 whole cell stain 
and incubated for 1 hr in the dark followed by final wash steps. Images were captured using the Operetta 
HTP microscope (Perkin Elmer) and analysis was carried out using Columbus Image Analysis software 
(Perkin Elmer). 
Animal Studies 
All animal experiments were performed under the relevant UK Home Office Project Licence and carried out 
with ethical approval from the University of Glasgow under the Animal (scientific Procedures) Act 1986 and 
the EU directive 2010. Mice were maintained in individually ventilated cages with environmental 
enrichment and ARRIVE guidelines followed. 
Intracranial tumour model 
Female CD1 nude mice were orthotopically injected with 1 x 10
5
 G7 cells into the subventricular zone as 
previously described [20, 22]. Tumours were allowed to establish for 10-11 weeks before magnetic 
resonance imaging (MRI) to confirm presence of tumour. Brain irradiation was performed on an XStrahl 
Small Animal Radiation Research Platform (SARRP) using parallel opposed beams and a 10 x 10 mm 
collimator to ensure adequate tumour coverage in all animals.  Mice were anaesthetised with isoflurane 
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and immobilised on a cradle with a tooth bar attachment.  A CT scan before irradiation allowed tissue 
segmentation and selection of an isocentre (approx. 5mm below cell injection drill hole). Dose distributions 
were uniform across the brain area as shown in Fig S2C. 5mg/kg BDP-9066 or vehicle (20% propylene 
glycol/80% PBS) was given subcutaneously twice daily or at stated time before cull for PK analysis. Tumours 
were sub-dissected and fresh frozen specimens sent for PK analysis (Vertex, UK). Formalin fixed, paraffin 
embedded sections were stained for Ki67, HLA or phosphoMYPT1 then scanned using a Hamamatsu 
Nanozoomer Slide scanning machine with Leica SlidePath Slide imaging software. Algorithms were 
optimised for each stain individually and automated, quantitative analysis undertaken. The defining of 
contralateral regions was performed blinded.  
MRI data acquisition and post-processing 
The animals were induced in an anaesthetic chamber with 5% isoflurane and a 30:70 O2/N2O ratio before 
being transferred to the MRI instrument animal cradle allowing to monitor respiration and temperature. 
Imaging experiments were performed on a Bruker Biospec Avance 7 T imaging system with a 30 cm 
horizontal bore (Bruker, Ettlingen, German). Homogeneous radiofrequency (RF) excitation was achieved 
using a birdcage volume resonator (diameter 72 mm, length 110 mm) and actively decoupled 4-channel 
phased array receive-only head surface coils were used for signal detection, with 22 mm length for mice 
and 35 mm length for rats (Rapid Biomedical, Wurzburg, Germany).  After standard spectrometer 
adjustments and geometry definition using a pilot sequence, T2 weighted imaging  was performed using a 
RARE sequence (Rapid Acquisition with Relaxation Enhancement); echo time=10 ms, repetition time=4,300 
ms, field of view = 176x176 mm,  matrix=176x176, slice thickness = 0.5 mm, 14 slices, RARE factor 8,  8 
min). MRI data were the exported in DICOM format for post-processing using an in-house MATLAB code. 
Tumour related abnormal regions were manually selected on each T2 slice. To evaluate tumour volumes, 
the number of voxels within abnormal regions was multiplied by the voxel volume. 
Results 
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MRCK activity is upregulated at the invasive edges of GBM tumours. Oncomine analysis of MRCK gene 
expression in GBM revealed ŵodest ďut sigŶifiĐaŶt upƌegulatioŶ of M‘CKα ŵ‘NA ǁheŶ Đoŵpaƌed to 
normal brain tissue (Fig.1A, [23, 24]), suggesting a possible role in GBM pathogenesis. In light of the 
established role of MRCK in cancer cell motility, we explored whether its activity was spatially regulated 
within the tumour to support GBM cell infiltration. Indeed, using a phospho-sensitive antibody that detects 
MRCKalpha autophosphorylation on S1003 (pS1003) as a validated biomarker of kinase activity (pMRCK), 
immunohistochemical staining of matched patient tumour core and margin samples showed that positivity 
, and by implication MRCKalpha activity, was largely restricted to invading GBM cells at the tumour margins 
(Fig.1B). In support of this observation, immunohistochemical analysis of primary human tumour cells in an 
intracranial GBM xenograft model revealed that MYPT1, the downstream target of MRCK, also showed 
increased phosphorylation levels in the cytoplasm of cells at the invasive edges of the tumours (Fig.1C). 
These data are consistent with a role for MRCK in supporting GBM tumour cell motility and invasion.  
The downstream targets of MRCK are upregulated by radiation in vitro and in vivo and this is associated 
with an increase in GBM invasion. Since the majority of GBM patients receive radiotherapy we explored 
whether MRCK activity was affected by radiation. As shown in Fig. 2A, Western blot analysis of two 
different primary human GBM cell lines, G7 and E2, showed that radiation induced an increase in 
phosphorylation levels of the MRCK biomarker, MYPT1. To confirm this observation, immunofluorescence 
analysis of pMLC2, another downstream biomarker of MRCK, was undertaken using a high throughput 
imaging platform and automated analysis (Fig.2B i, ii). This unbiased technique clearly indicated a 
significant increase in pMLC2 levels upon irradiation of GBM cells in vitro. Furthermore, a significant 
increase in the average pseudopod length was observed in irradiated cells, suggesting that the activation of 
MLC2 by RT is driving actin-myosin cytoskeletal changes that may promote motility (Fig. 2B iii). 
To confirm that this phenomenon also occurs in vivo, histological staining and automated analysis of 
pMYPT1 levels was performed in samples from whole-brain irradiated (3 x 2Gy fractions) and non-
irradiated cohorts of mice bearing intracranial G7 xenograft tumours that were sacrificed 5 days after the 
final radiation dose. Although no significant change in nuclear pMYPT1 was detected, we observed 
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significant upregulation of cytoplasmic pMYPT1 both at the invasive tumour edge (Fig. 2C i and ii) and in the 
tumour core (Fig. 2C iii). This suggests that MRCK activity is not only upregulated acutely, and throughout 
the tumour, by irradiation, but may also ďe ŵaiŶtaiŶed ďǇ a loŶgeƌ teƌŵ ͚sǁitĐh͛ iŶ iŶtƌaĐellulaƌ sigŶalliŶg. 
In support of this hypothesis, analysis of tumours from smaller cohorts of mice sacrificed 12 days after the 
final radiation dose also showed significant upregulation of pMYPT1 (Fig. 2C iv). 
Since radiation induced migration of GBM cells has recently been reported by a number of groups, and 
MRCK activity is known to have pro-migratory effects, we questioned whether radiation would affect cell 
migration. To interrogate this important question we used complementary experimental approaches in 
three different model systems. The invasive behaviour of cancer cells can be affected by their intrinsic 
ability to produce the cytoskeletal rearrangements required for forward migration as well as their ability to 
modify their surroundings to produce a pro-migratory environment (e.g. by degradation of extracellular 
matrix). Having observed a radiation induced increase in MRCK biomarkers, we first used a simple sub-
confluent migration assay coupled with single cell tracking to assess whether radiation affects the intrinsic 
mechanisms of migration, without the complications of extracellular matrix and brain architecture (Fig.3A). 
These experiments showed that irradiated cells from two different primary GBM cell lines (E2 and G7) 
migrated significantly faster than non-irradiated cells, indicating that radiation enhances the mechanical 
motility of GBM cells. 
To explore whether this pro-migratory effect was maintained when GBM cells have to negotiate the 
complexities of the brain microenvironment, we employed an ex vivo migration assay (fig 3B, sup. video 1 
and 2). Fluorescently labelled E2 and G7 GBM cell lines were seeded onto fresh murine brain slices and 
their migration speed measured using confocal time-lapse microscopy and single cell tracking. We tracked 
>50 cells per condition encompassing all routes of invasion (i.e. perivascular and along white matter tracts) 
to obtain accurate average migration speeds. We observed that the average speed of cells in this assay was 
slower that in 2D, suggesting the brain structure poses a barrier to the invading GBM cells and that their 
migration in this environment requires additional processes such as extracellular matrix remodelling. 
However, as with the 2D migration assay, we observed that cells irradiated prior to being seeded onto the 
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brain slices moved significantly faster than control cells, indicating that the pro-migratory effect of radiation 
is maintained within the brain environment. 
Finally, we demonstrated that radiation induces invasion in vivo by quantifying migration of GBM cells away 
from the primary tumour mass in control and irradiated cohorts of mice implanted with intracranial GBM 
xenografts (Fig. 3C). Primary human G7 GBM cells injected into the sub-ventricular zone form a tumour 
mass in the ipsilateral hemisphere with invasive edges. Over time, cells leave the invasive tumour edge and 
migrate to the contralateral hemisphere. This allows for a simple analysis of the migratory potential of 
tumours cells by analysing the number of tumour cells that have reached the contralateral hemisphere. To 
enable automated and unbiased quantification, brain sections from mice culled 17 days after initiation of 
radiation treatment were stained for the nuclear proliferation marker Ki67, which discriminates clearly 
between replicating tumour cells and the non-proliferating cells of the mouse brain (Fig. 3C i – iii). Mice had 
undergone T2-weighted magnetic resonance imaging (MRI) to confirm the presence and equivalence of size 
of tumours 11 weeks after tumour cell injection (Fig.S1 A). No effect on Ki67 staining within the tumour 
bulk was detected, indicating that GBM cell proliferation was unaffected by these radiation doses and 
would therefore not affect quantification of invading cells. In contrast, analysis of the contralateral 
hemisphere showed significantly higher numbers of Ki67 positive tumour cells in irradiated mice, strongly 
supporting the concept that radiation promotes infiltration of tumour cells to distant sites within the brain 
in a relevant in vivo mouse model. Although Ki67 staining provides a clear nuclear stain that simplifies 
automated analysis of histology sections, a caveat to this approach it that it would fail to detect non-
proliferating GBM cells. To validate the data we also stained sections for the human Leukocyte Antigen 
(HLA Class I ABC). We found that Ki67 and HLA staining correlated well (Fig. S1 B), and observed increased 
numbers of HLA positive cells in the contralateral hemispheres of the irradiated cohort, confirming the 
observations made with Ki67 (Fig. 3C iii). 
MRCK plays an essential role in driving radiation induced migration. To probe whether increased cell 
migration requires enhanced MRCK activity, and to assess its relative contribution, we performed 
subconfluent migration assays in G7 cells in which M‘CKα aŶd β had been downregulated by siRNA 
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targeting (Fig.4A and B). Ablation of both MRCK isoforms concomitantly was found to inhibit pMYPT1 
expression and to reduce migration speed to the levels observed in non-irradiated control cells. These 
findings strongly indicate that MRCK, and not ROCK, is primarily responsible for the downstream signalling 
to MYPT1 and MLC2 that drives radiation induced migration in GBM cells. 
Specific targeting of MRCK, but not ROCK, using a novel small molecule inhibitor, does not affect cell survival 
but elicits a robust biomarker and motility dose response at sub-micromolar concentrations. We have 
developed a novel small molecule inhibitor, BDP-ϵϬϲϲ, that displaǇs high seleĐtiǀitǇ toǁaƌds M‘CKα/β oǀeƌ 
related kinases such as ROCK ([17], Fig.4C, Supp. Table 2). BDP-9066 demonstrates excellent selectivity for 
M‘CKα aŶd M‘CKβ oǀeƌ the closely related kinases ROCK1 and ROCK2. Furthermore, BDP-9066 also shows 
eǆĐelleŶt seleĐtiǀitǇ ǁheŶ sĐƌeeŶed iŶ a laƌgeƌ kiŶase paŶel ;ϭμM BDP-9066 against 113 kinases; 7/113 
kinases show inhibition >80%, [17]). The biochemical activity and selectivity of BDP-9066 was maintained in 
cellular assays. 
To test whether BDP-9066 had any impact on tumour cell survival either as a single agent or in combination 
with radiation we performed cell viability and clonogenic survival assays. No effect on viability was 
observed at sub-micromolar levels of BDP-9066 (Fig.4C i), and 250 nM BDP-9066 had no impact on the 
radiation sensitivity of G7 or E2 cells as measured by clonogenic survival (Fig.4 ii) despite compound being 
in excess of the IC50 indicated in Fig 4D i. The loss of cell viability at higher concentrations is likely to 
represent off target toxicity. Confirmation that BDP-9066 is inhibiting its target is provided by the robust 
dose response of the MRCK biomarker pMLC2 in irradiated GBM cells as measured by immunofluorescence 
(IC50 = 56nM; Fig. 3D i). The response of non-irradiated GBM cells to the inhibitor was highly variable, 
suggesting a lack of synchronicity of MRCK activity in unirradiated cells. In contrast, when we tested BDP-
9066 in our in vitro and ex vivo migration assays we found that the compound completely blocked the 
radiation induced increase in cell motility observed in subconfluent migration assays at a concentration of 
100nM (Fig. 4E). This anti-invasive activity of BDP-9066 was also confirmed using the organotypic ex vivo 
brain slice assay (Fig. 4F). Further experiments showed a robust dose response of irradiated cells to BDP-
9600 in subconfluent migration assays (Fig. 4G i). Importantly, treatment with the ROCK specific inhibitor 
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Y27632 did not inhibit migration of irradiated cells (Fig. 4G ii), providing further evidence that the pro-
invasive effect of RT is primarily driven through MRCK activation. 
Pharmacological inhibition of MRCK inhibits radiation induced infiltration by GBM cells in vivo. Compound 
level analysis of sub dissected intracranial U87MG and G7 tumours indicated that BDP-9066 penetrated 
intracranial tumours at concentrations that would be expected to inhibit of MRCK in vivo, even when 
adjusted for free drug levels (based on plasma protein binding of 27.3%; Fig. 5A). Samples taken from the 
contralateral hemisphere showed that BDP-9066 has very low exposure in the brain in the absence of 
significant tumour burden, following subcutaneous dosing. To test the efficacy of BDP-9066 in inhibiting 
radiation induced invasion in vivo we established G7 intracranial tumours in four cohorts of mice: vehicle, 
BDP-9066, RT + vehicle and RT + BDP-9066. Mice underwent T2-weighted MRI to confirm the presence and 
equivalence of size of tumours 11 weeks after tumour cell injection (Fig. S2A); treatment was commenced 
the following week. Mice in the RT cohorts received 3 x 2Gy whole brain RT over the course of one week 
(Fig S2 B). Twice daily dosing of vehicle or BDP-9066 was initiated at the same time as RT and continued for 
10 days before sacrifice of the animals to ensure sustained inhibition of MRCK (Fig. 5B). Twice daily dosing 
was chosen because, while the pharmacokinetic (PK) profile of BDP-9066 showed good bioavailability, rapid 
clearance was also observed [17]. The compound was well tolerated and PK analysis of blood taken at the 
time of culling confirmed its presence at micromolar concentrations (Fig. S2 C). A transient vasodilatory 
effect lasting 20 - 30 minutes was noted in some animals as evidenced by reddening of the ears.   
Mouse brains were excised and subjected to immunohisochemical analysis of Ki67 staining. Consistent with 
our previous experiment, increased numbers of GBM cells were observed in the contralateral hemispheres 
of mice in the ͚irradiated + vehicle͛ cohort (Fig.5C). Importantly, irradiated mice that were treated with 
BDP-9066 showed no increase of tumour cell infiltration to the contralateral hemisphere. These data 
confirm that BDP-9066 prevents radiation induced infiltration of GBM in vivo. Immunohistological staining 
for the MRCK biomarker pMYPT1 (Fig. 5C ii) showed reduced expression in the RT + BDP-9066 cohort 
compared to RT + vehicle, indicating that the anti-invasive effects of the inhibitor are likely ͚on target͛. 
14 
 
BDP-9066 induces an aberrant morphology through the disruption of the actin-myosin cytoskeleton in GBM 
cells. In vitro and ex vivo timelapse imaging of cells treated with BDP-9066  revealed the emergence of an 
aberrant morphology characterised by increased numbers of neurite-like structures emanating from the 
cell body that appeared to prevent migration (Sup. video 3 -6). To characterise this further, high throughput 
imaging was performed on irradiated E2 cells in which the actin cytoskeleton had been stained with 
fluorescently labelled phalloidin (Fig.6A). Cells treated with BDP-9066 exhibited a highly disordered 
cytoskeletal structure, indicating that MRCK inhibition disrupts normal actin-myosin dynamics, leading to 
the aberrant morphology and reduced migratory potential observed. To explore this further, automated 
analysis was undertaken to measure the number of neurite roots in response to escalated doses of BDP-
9066 in both irradiated and untreated cells (Fig.6B). Neurite numbers increased in a dose dependent 
manner under both conditions, but as with the pMLC2 biomarker response (Fig. 4D), data from non-
irradiated cells was highly variable compared to irradiated cells. This provides further evidence that 
radiation synchronises MRCK activity across the cell population, rendering more cells sensitive to inhibition 
by BDP-9066 and eliciting a more uniform and more striking response. 
Treatment with BDP-9066 significantly increases survival in a pre-clinical model of GBM. To assess whether 
inhibiting the invasive capacity of GBM cells in vivo confers a survival benefit, we performed an extended 
efficacy experiment using the G7 intracranial tumour model (fig. 7A). Tumours were allowed to establish 
for 9 weeks before the mice underwent T2-weighted MRI to establish tumour establishment and enable 
randomisation of mice into cohorts, stratified by tumour size. Treatment commenced at week 10 on mice 
randomised into 4 cohorts: no RT + vehicle, no RT + BDP-9066, RT + vehicle and RT + BDP-9066. RT was 
fractionated into 6 x 2Gy over two weeks. BDP-9066 or vehicle (blinded) was administered twice daily, 
Monday- Friday, for a total of four weeks (two weeks concomitant with and two weeks adjuvant after RT). 
Treatment was limited to 4 weeks under veterinary guidance to reduce the stress of repeat dosing on the 
animals. Mice were culled upon presentation of clinical symptoms (weight loss, seizures, tilting etc). Only 
mice that were culled after the first week of treatment were included in the survival analysis to provide 
adequate time for treatment to take effect. The experiment was terminated at 104 days after T2 weighted 
MRI scans had been performed on the remaining mice. 
15 
 
The results clearly indicate that, while RT alone provided a survival benefit, this was significantly enhanced 
when combined with BDP-9066, despite the inhibitor only being administered for a restricted period of 
time (Fig. 7B). Additionally, although quantitation of contralateral invasion could not be applied in this 
experiment as the mice were culled at varying time points, histological analysis indicates that tumours from 
the RT + BDP-9066 cohort are more contained with less invasive margins than RT + vehicle cohort (Fig. 7C). 
Indeed qualitative assessment of invasion extent showed that 8 out of 14 RT + vehicle mice showed 
extensive contralateral invasion compared to only 3 out of 13 RT+ BDP-9066 mice. The variation in cull time 
also means that any potential effect on tumour size could not be assessed in this experiment as mice were 
culled at clinical endpoint and thereby all likely to be carrying a significant tumour burden.  These data 
provide important evidence that adding a novel MRCK targeting, anti-invasive small molecule treatment to 
radiation therapy has the potential to improve outcomes in this cancer of unmet need by negating the 
adverse, pro-invasive effects of radiation.  
Discussion  
Glioblastoma is the most aggressive primary brain tumour in adults and the least responsive to treatment. 
These adverse clinical features are partly attributable to the infiltrative nature of the disease. Glioblastoma 
cells undergo a number of biological and morphological changes that allow them to migrate through the 
perivascular spaces and white matter tracts of the brain. The role that RhoGTPases and their effector 
kinases play in these processes have been interrogated by a number of researchers [12], and inhibition of 
CDC42, the upstream activator of MRCK, has been shown to inhibit migration of glioma cells [25-27]. 
However, little is known about the effects of ionising radiation on these pathways and the subsequent 
downstream effects on migration and invasion. In addition, by augmenting actin-myosin cytoskeleton 
plasticity through targeting the upstream regulator MRCK, we are hitting a regulatory node that is a 
convergence point for a number of signalling pathways that have previously shown to be important in GBM 
invasion such as integrin and FAK signalling [28] [29, 30]. 
Analysis of MRCK gene expression using Oncomine datasets indicated that, whilst expression is raised in 
tumour samples compared to the normal brain, this increase is modest. We postulated that overall gene 
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expression levels might fail to reflect more pronounced upregulation at the tumour margins, where 
increased MRCK activity may be required to support tumour cell infiltration of the healthy brain tissue. 
Such spatial restriction of gene expression has been documented for other pro-migratory factors such as 
EGFR [31, 32]. By measuring MRCK-specific auto-phosphorylation at Ser1003 in patient derived tumour 
core and tumour margin samples we observed that MRCK activity is indeed specifically upregulated in 
infiltrating GBM cells, indicating an important influence of this signalling pathway on invasion. Furthermore 
we demonstrated that exposure to radiation further increases MRCK signalling to drive increased migration 
both in vitro and in a clinically relevant intracranial GBM tumour model. Interestingly, this radiation induced 
activation of MRCK extended into the tumour core whereas in the absence of radiation MRCK activation 
biomarkers were observed only at the tumour margin.  This indicates that MRCK activation by RT is not 
restricted to cells at the tumour margin and therefore may have potential to drive other biological 
processes within the tumour core. 
The question of whether radiation promotes the invasive behaviour of GBM cells has been controversial for 
many years. However, recent publications from a number of research groups [5-7] and the data presented 
here provide robust evidence in support of this phenomenon and highlight the potential value of 
incorporating anti-invasive strategies into standard first line therapy for GBM. While the observation that 
most glioblastomas recur within the maximally irradiated volume [33-35] has been used as an argument 
against radiation induced invasion being of clinical relevance, an alternative explanation is that local 
tumour recurrence is caused by repopulation of the irradiated tumour bed by tumour cells from outside the 
irradiated volume. Evidence for repopulation of laser ablated regions of tumour by GBM cells was recently 
presented by Osswald et al [36] and may represent a novel and important mechanism of treatment 
resistance. Such a model also is supported by the observation that a significant proportion of tumours recur 
at the periphery of the irradiated volume [33]. This mechanism of tumour recurrence would require 
surviving GBM cells to retain their invasive capacity and would also be consistent with the well documented 
failure of radiation dose escalation to either reduce tumour recurrence rates or reduce the incidence of 
recurrence within the irradiated volume [8, 37, 38]. 
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Our data support the theory that novel anti-invasive chemotherapeutics for GBM should always be 
evaluated in the context of radiotherapy, not only because of the pro-invasive effects of radiation, but also 
to ensure that candidate compounds are active against tumour cells whose signalling pathways have been 
fundamentally altered by radiotherapy.  Our results show that, while ablation of MRCK activity effectively 
inhibited the migration and infiltration of irradiated cells, there was a reduced effect on non-irradiated 
control cells in vitro and in vivo. Furthermore, our results indicate that radiation induced effects on 
glioblastoma cells in vivo are not transient but can persist for days after the conclusion of radiotherapy.  
Our study utilised a novel, highly specific inhibitor of MRCK, BDP-9066 that was developed in-house by the 
CRUK Beatson Drug Discovery Programme. Treating primary GBM cells with this compound in vitro revealed 
that MRCK inhibition induces a highly aberrant morphology characterised by disordered, neurite-like 
protrusions. Not only do these morphological changes appear to prevent GBM cells from migrating 
persistently, they may have additional implications for GBM biology and resistance to therapy. Winkler et al 
recently published an elegant study that identified a network of communicating glioma cell protrusions, 
teƌŵed ͚tuŵouƌ ŵiĐƌotuďes ;TMͿ͛, which contributed to chemo- and radioresistance in vivo [36, 39-41]. 
Since TM formation is highly dependent on cytoskeletal dynamics and BDP-9066 specifically induces 
aberrant protrusions, it is possible that MRCK inhibition will exert therapeutic effects in vivo by disrupting 
the TM communication network. 
As part of our in vivo studies we demonstrated that BDP-9066 penetrates intracranial tumours in two 
different mouse models of GBM at levels that far exceeded the biomarker IC50 values calculated for 
irradiated GBM cell lines. Drug levels in the contralateral hemisphere were much lower, reflecting limited 
penetration of the intact blood-brain barrier, which may be of value in protecting normal brain cells and 
reducing toxicity. Conversely, delivery of BDP-9066 to regions of low tumour cell density may be 
compromised by limited BBB disruption, although evidence exists that suggest that focal disruption of the 
BBB can be elicited by single invading glioma cells [42]. To maximize efficacy it may be advantageous to 
develop the current series of compounds to include a more BBB penetrant molecule that would penetrate 
areas of very low tumour burden. Most importantly, our results demonstrate conclusively that BDP-9066 
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completely blocks the pro-invasive effects of radiation on GBM cells, preventing them from disseminating 
to intracranial sites distant from the primary tumour; this effect translated in to a survival benefit when 
BDP-9066 was given in combination with RT.  
As mentioned previously, the development of effective ROCK inhibitors for clinical use has been hindered 
by severe adverse effects on the cardiovascular system. Although we observed a mild vasodilatory effect in 
some animals, to date, we have no evidence that MRCK inhibition would elicit a similarly intolerable 
response to ROCK inhibition, but such a possibility should be carefully considered during optimisation of 
MRCK specific compounds for clinical use. 
This study did not extend to investigating the combination of BDP-9066 in combination with both RT and 
temozolomide (TMZ). SInce TMZ is a component of standard of care for GBM patients it will be important 
to determine whether it modulates the interaction between RT and MRCK inhibition as this novel 
treatment strategy progresses towards the clinic.  
In conclusion, our data provides novel and persuasive evidence that delivery of BDP-9066 or a related 
compound alongside radiotherapy has potential not only to extend survival of patients with GBM, but also 
to improve the devastating neurological symptoms associated with these infiltrative tumours. 
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Figure 1. MRCK activity is upregulated at the invasive edge of GBM tumours. (A) Oncomine analysis of 
data from two separate studies indicating increased MRCKα mRNA expression in clinical GBM samples 
compared to normal brain tissue. (B) Matched tumour margin and tumour core samples were obtained 
from patients with GBM and stained for an MRCK activity auto-phosphorylation site, S1003. Cytplasmic 
pMRCK levels were quantified using automated analysis on SlidePath. Statistical analysis: two tailed, 
unpaired t test. N.S. = not significant, ** p < 0.01. (C) Example image from samples obtained from a G7 
intracranial tumour mouse model stained for pMYPT1, a downstream target of MRCK.  
 
Figure 2. MRCK activity is stimulated by radiation in vitro and in vivo (A) Two primary cell lines, E2 and G7, 
were treated with 0, 2 or 5 Gy and protein lysates extracted after 24 hours. Western blot analysis was 
undertaken to assay levels of pMYPT1. Actin and tubulin were used as loading controls and γ-H2AX as a 
marker of radiation induced DNA damage. (B) (i) E2 cells were treated with 0 or 2 Gy and stained by 
immunofluorescence for pMLC2. Cells were imaged using an Operetta high-throughput imaging platform. 
Green: pMLC2; yellow: actin; red: whole cell dye; blue: DAPI; Final panel: merge. Scale bar: 100μm. (ii) 
Automated image analysis was undertaken to compare pMLC2 levels in control and irradiated cells. (iii) 
Pseudopod length was quantified using automated image analysis. Data are derived from two biological 
repeats, each analysing >400 cells per condition. Statistical analysis: two tailed, unpaired t test. **** p < 
0.0001 (C) Cohorts of mice bearing G7 intracranial tumours were subjected to 3 x 2Gy fractions of whole 
brain irradiation or left untreated. Brain sections were stained by IHC for pMYPT1 levels (i). (ii), (iii) Levels 
of nuclear and cytoplasmic pMYPT1 were quantified in mice sacrificed 5 days post RT. (iv) Levels of 
cytoplasmic pMYPT1 were measured 12 days post RT. Quantification was done via automated analysis 
using SlidePath ; n = 5 (no RT) and 6 (3 x 2 Gy), 5 day timepoint; n = 4 (no RT) and 4 (3 x 2 Gy), 12 day time 
point . Scale bar: 100μm. Statistical analysis: two tailed, unpaired t test. N.S. = not significant, * p < 0.05.  
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Figure 3. Activation of MRCK by radiation is concomitant with increased motility of GBM cells in vitro and 
in vivo. (A) E2 and G7 were treated with 0 or 2Gy and their motility analysed in a sub-confluent migration 
assay using time-lapse microscopy and single cell tracking. (i) Example track plots of individual control and 
irradiated E2 cells imaged over 16 hours, 15 min intervals. (ii) Comparison of control and irradiated cell 
speed. (B) Fluorescently labelled E2 or G7 cells were irradiated with 2Gy or left untreated and seeded onto 
fresh murine brain slices. Cell motility was analysed using confocal time-lapse microscopy (i). (ii) Cell speed 
was measured using single cell tracking. Data fƌoŵ ϯ ďiologiĐal ƌepliĐates. SĐale ďaƌ: ϱϬμŵ StatistiĐal 
analysis: Mann-Whitney test, ** p < 0.005, **** p < 0.0001. (C) (i) Brain sections from control and 
irradiated mice bearing G7 intracranial tumours were stained via IHC for Ki67 to indicate presence of 
cycling GBM tumour cells. (ii) % Ki67 positive cells in the tumour bulk were quantified using automated 
analysis in specimens from mice culled 10 days after initiation of treatment; n = 6 in both cohorts. The 
percentage of Ki67 positive cells (iii) or HLC (iv) in the contralateral hemisphere of mice culled 17 days after 
initiation of treatment was quantified using automated image analysis. Scale bar: 1mm. Statistical analysis: 
two tailed, unpaired t test. N.S. = not significant, ** p < 0.005.  
 
Figure 4. Inhibition of MRCK activity opposes radiation driven motility but does not affect cell survival in 
vitro. (A) Gϳ Đells ǁeƌe tƌaŶsfeĐted ǁith si‘NAs taƌgetiŶg M‘CKα aŶd M‘CKβ, aloŶe oƌ iŶ ĐoŵďiŶatioŶ. ;iͿ 
Cell lysates were analysed by Western blottiŶg foƌ M‘CKα, M‘CKβ aŶd pMYPTϭ leǀels. ;iiͿ Tƌeated Đells 
were exposed to 0Gy or 2Gy and imaged in a sub-confluent migration assay. Cell speed was measured by 
single cell tracking. Statistical analysis: Mann-Whitney test, N.S. = not significant, *< p 0.05, ** p < 0.005, 
*** p < 0.001. (B) Novel MRCK specific inhibitor, BDP-9066. (C) (i) Cell viability assays performed on G7 cells 
treated with increasing concentrations of BDP-9066;d data plotted relative to vehicle control. (ii) 
Clonogenic survival assays peƌfoƌŵed oŶ Gϳ aŶd EϮ Đells iƌƌadiated iŶ the pƌeseŶĐe of ǀehiĐle oƌ Ϭ.Ϯϱ μM 
BDP-9066. N.S. = not significant. (D) E2 cells treated with 2 Gy radiation (i) or untreated (ii) in the presence 
of increasing amounts of BDP-9066, and stained by immunofluorescence for pMLC2. Cells were imaged 
using an Operetta high-throughput imaging platform. Automated image analysis was used to compare 
pMLC2 levels. Data from two biological repeats with >400 cells per condition per biological replicate. Data 
plotted as a percentage of vehicle. (E) E2 and G7 cells were exposed to 0 Gy or 2 Gy radiation in the 
presence of DMSO or BDP-9066 and cell speed measured in a subconfluent migration assay using timelapse 
microscopy and single cell tracking. Data from 3 biological replicates. (F) Fluorescently labelled E2 cells 
were exposed to 0 Gy or 2 Gy radiation and seeded onto fresh murine brain slices. Cell motility was assayed 
in the presence of DMSO or BDP-9066 by confocal timelapse microscopy and single cell tracking using 
ImageJ. Data from 3 biological replicates. For all in vitro and ex vivo motility assays statistical analysis was 
performed using Mann-Whitney test: N.S. = not significant, *< p 0.05, ** p < 0.005, *** p < 0.001, ****p < 
0.0001. (G) E2 and G7 cells were exposed to 2 Gy in the presence of increasing amounts of BDP-9066 (i) or 
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Y-27632 followed by timelapse microscopy and single cell tracking. Data from 3 biological replicates. 
Baseline speed was calculated to be 34 from the measurement of >20 non-migratory cells. 
 
Figure 5. BDP-9066 penetrates intracranial GBM xenografts and inhibits radiation induced infiltration of 
GBM cells in vivo. (A) Mice bearing U87MG (i) or G7 (ii) intracranial tumours were injected subcutaneously 
with 5 mg/Kg BDP-9066 30 mins prior to cull. Tumours were sub-dissected from normal brain tissue and 
aŶalǇsed ďǇ ŵass speĐtƌoŵetƌǇ to deteƌŵiŶe total ĐoŵpouŶd leǀels ;͚Total͛Ϳ. These leǀels ǁeƌe adjusted 
using a determined PPB free value of 72.7 % to estimate available BDP-9066 levels in the tumours ;͚Fƌee͛Ϳ; Ŷ 
= 4 (U87MG) and 10 (G7); CL = contralateral. (B) Outline of experiment to measure in vivo GBM cell 
response to BDP-9066. G7 intracranial tumours were allowed to establish for 12 weeks before initiation of 
treatment. (C) Cohorts of mice from (B) were culled and excised brains subjected to IHC for Ki67 followed 
by automated analysis to determine extent of contralateral hemisphere invasion by GBM cells. 
 
 Figure 6. BDP-9066 treatment disrupts the actin-myosin cytoskeleton inducing an aberrant morphology 
that inhibits migration.  (A) (i) E2 cells were exposed to 0 or 2 Gy radiation in the presence of DMSO or 
BDP-9066. Cells were imaged using an Operetta high-throughput imaging platform. Red: actin, blue: DAPI, 
SĐale ďaƌ: ϭϬϬμŵ. ;iiͿ Autoŵated iŵage aŶalǇsis ǁas uŶdeƌtakeŶ to ƋuaŶtifǇ Đhanges in neurite 
morphology. Data from > 1000 cells. (B) Radiation stimulates MRCK activity, activating MLC2 and driving 
actin-myosin contractility and subsequent cell migration. Treatment with BDP-9066 inhibits MRCK activity 
resulting in a disrupted actin-myosin cytoskeleton and loss of motility. 
 
Figure 7. Combining BDP-9066 with RT confers a significant survival advantage on mice bearing 
intracranial GBM tumours. (A) Outline of experiment to measure in vivo survival to BDP-9066 treatment. 
G7 intracranial tumours were allowed to establish for 10 weeks before initiation of treatment. Mice in the 
RT cohorts received 6 x 2Gy whole brain RT over the course of two weeks. Only mice that were culled after 
the first 3 fractions of RT were included in the analysis to allow for any treatment benefit to take effect. The 
study was randomised, blinded and the mice stratified across the cohorts based on starting tumour size as 
assessed by T2 MRI. (B) Kaplan-Meier plot showing survival data. N.S. = not significant, *< p 0.05, ** p < 
0.005. Statistical analysis: Log-rank (Mantel-Cox) test. (C) Example histology from RT + vehicle and RT + 
BDP-9066 cohorts 
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